Ventricular remodeling

From WikiMD's WELLNESSPEDIA


Overview[edit]

Illustration of a myocardiocyte, a key cell type involved in ventricular remodeling.

Ventricular remodeling refers to the changes in size, shape, structure, and function of the heart's ventricles following cardiac injury, such as a myocardial infarction. This process can lead to heart failure if the remodeling is maladaptive. Ventricular remodeling involves complex interactions between cardiomyocytes, the extracellular matrix, and various signaling pathways.

Pathophysiology[edit]

Ventricular remodeling is initiated by the death of cardiomyocytes due to ischemic injury. The loss of viable myocardium triggers a cascade of events, including inflammation, fibrosis, and hypertrophy of the remaining myocytes. These changes are mediated by neurohormonal activation, including the renin-angiotensin-aldosterone system and the sympathetic nervous system.

Cellular Changes[edit]

The primary cellular change in ventricular remodeling is the hypertrophy of myocardiocytes. This hypertrophy is an adaptive response to increased wall stress and is characterized by an increase in cell size and protein synthesis. However, prolonged hypertrophy can lead to cell death and further deterioration of cardiac function.

Extracellular Matrix[edit]

The extracellular matrix (ECM) undergoes significant remodeling during this process. There is an initial degradation of the ECM, followed by excessive deposition of collagen and other matrix proteins, leading to fibrosis. This fibrosis increases the stiffness of the ventricular wall and impairs diastolic function.

Clinical Implications[edit]

Ventricular remodeling is a critical determinant of the clinical outcome following a myocardial infarction. Patients with significant remodeling are at higher risk of developing heart failure and have a worse prognosis. Therapeutic strategies aimed at preventing or reversing remodeling include the use of ACE inhibitors, beta-blockers, and aldosterone antagonists.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.